Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • William Blair Hosts 46th Annual Growth Stock Conference

    William Blair today kicked off its 46th Annual Growth Stock Conference, convening companies and institutional investors from around the globe for three days of presentations and one-on-one meetings.

    Read more

  • Monthly Macro: Resilient Equities, Rising Yields, and a Shifting Playbook

    As geopolitical tensions persist and inflation concerns resurface, equity markets remain resilient while bond markets signal a more cautious outlook. Richard de Chazal unpacks what’s driving this divergence, the durability of the U.S. consumer, and why quality may be coming back into focus.

    Listen to the podcast

  • Sentinel Dock & Door Solutions Has Been Acquired by ASSA ABLOY

    William Blair acted as the exclusive financial advisor to Sentinel Dock & Door Solutions, a portfolio company of Trivest Partners, in connection with its sale to ASSA ABLOY.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures